Eli Lilly: Trump's Pricing Policy to Impact Obesity Drug Launches in Europe
📊 LLY — Piyasa Yorumu
▼ down · 60%The news indicates that the Trump administration's pricing policies could negatively impact Eli Lilly's obesity drug launches in Europe. This may heighten concerns about the company's growth potential. Technical indicators also point to weakness: the RSI is at 48, in neutral territory but with a downward bias; the MACD is below zero and, although above the signal line, remains in negative territory. The price is trading just above the 20-day moving average (1102.55) but well below the 50-day moving average (1121.25). Selling pressure is likely to persist in the short term.
📊 GOOGL — Piyasa Yorumu
▼ down · 65%Although GOOGL shares closed 4.5% lower in the last session and the Relative Strength Index (RSI) at 36 is approaching oversold territory, the Moving Average Convergence Divergence (MACD) continues to issue a sell signal. While the news headline does not directly concern Alphabet, the impact of Trump's pricing policies on the pharmaceutical sector could also spill over into technology stocks. Technically, the price is trading below both the 20-day and 50-day moving averages, suggesting that short-term pressure may persist. However, the pace of the decline and the low RSI level also indicate some potential for a rebound.